Molbio Diagnostics Limited has fixed its initial public offering (IPO) price band between ₹768 and ₹807 per equity share of face value Re 1. The subscription for the IPO will open on August 10 and close on August 12, with anchor investor allocations scheduled for August 7, according to livemint.com.
The company has set a minimum lot size of 18 shares for retail investors. The IPO price band was announced ahead of the subscription window, allowing investors to prepare for participation. The anchor investor allotment on August 7 will precede the public subscription period, providing early commitments to the offering.
This IPO price band positions Molbio Diagnostics in a competitive range within the diagnostics sector, reflecting investor interest in healthcare and biotech firms. The move follows a trend of increased market activity in the diagnostics space, with several companies seeking public listings to fund expansion and innovation. The pricing strategy aims to balance valuation with market appetite, aligning with recent sector offerings.
The IPO subscription period from August 10 to August 12 will determine investor demand and final pricing. The anchor investor allocation on August 7 will set the tone for the public offering. Market participants will watch subscription levels closely as the company moves toward listing.